A phase 1 study of CS-3003 in patients with advanced solid tumors and relapsed or refractory multiple myeloma
Latest Information Update: 18 Mar 2019
At a glance
- Drugs CS 3003 (Primary)
- Indications Multiple myeloma; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 18 Mar 2019 New trial record
- 12 Mar 2019 According to a CStone Pharmaceuticals media release, the National Medical Products Administration (NMPA) recently approved Investigational New Drug application for CS3003 for Phase I clinical trial.